| 2025年年报 | 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|---|
| 营业收入(元) | ||||
| 大分子和细胞与基因治疗服务(元) | 474,691,180.34 | 211,476,697.22 | 407,518,945.43 | 211,210,409.44 |
| 临床研究服务(元) | 1,956,668,993.89 | 939,326,620.21 | 1,826,208,312.35 | 843,269,367.02 |
| 实验室服务(元) | 8,158,884,614.98 | 3,892,461,316.76 | 7,046,874,518.81 | 3,371,176,816.35 |
| 化学和制剂工艺开发及生产(元) | - | - | - | 1,175,747,332.83 |
| CMC(元) | 3,482,931,712.52 | 1,389,706,924.83 | 2,988,773,210.09 | - |
| 营业成本(元) | ||||
| 大分子和细胞与基因治疗服务(元) | 666,019,418.97 | 327,167,475.04 | 611,581,976.13 | 277,410,915.35 |
| 临床研究服务(元) | 1,733,466,591.79 | 823,559,155.64 | 1,592,025,240.46 | 737,427,319.21 |
| 实验室服务(元) | 4,479,578,588.07 | 2,132,974,433.48 | 3,881,177,854.47 | 1,872,495,689.01 |
| 化学和制剂工艺开发及生产(元) | - | - | - | 843,026,164.32 |
| CMC(元) | 2,287,934,417.27 | 965,827,677.46 | 1,984,068,508.56 | - |
| 毛利(元) | ||||
| 大分子和细胞与基因治疗服务(元) | -191,328,238.63 | -115,690,777.82 | -204,063,030.70 | -66,200,505.91 |
| 临床研究服务(元) | 223,202,402.10 | 115,767,464.57 | 234,183,071.89 | 105,842,047.81 |
| 实验室服务(元) | 3,679,306,026.91 | 1,759,486,883.28 | 3,165,696,664.34 | 1,498,681,127.34 |
| 化学和制剂工艺开发及生产(元) | - | - | - | 332,721,168.51 |
| CMC(元) | 1,194,997,295.25 | 423,879,247.37 | 1,004,704,701.53 | - |
| 毛利率(%) | ||||
| 大分子和细胞与基因治疗服务(%) | -40.31 | -54.71 | -50.07 | -31.34 |
| 临床研究服务(%) | 11.41 | 12.32 | 12.82 | 12.55 |
| 实验室服务(%) | 45.10 | 45.20 | 44.92 | 44.46 |
| 化学和制剂工艺开发及生产(%) | - | - | - | 28.30 |
| CMC(%) | 34.31 | 30.50 | 33.62 | - |
| 收入构成(%) | ||||
| 大分子和细胞与基因治疗服务(%) | 3.37 | 3.29 | 3.32 | 3.77 |
| 临床研究服务(%) | 13.90 | 14.60 | 14.88 | 15.05 |
| 实验室服务(%) | 57.97 | 60.51 | 57.43 | 60.18 |
| 化学和制剂工艺开发及生产(%) | - | - | - | 20.99 |
| CMC(%) | 24.75 | 21.60 | 24.36 | - |
| 毛利构成(%) | ||||
| 大分子和细胞与基因治疗服务(%) | -3.90 | -5.30 | -4.86 | -3.54 |
| 临床研究服务(%) | 4.55 | 5.30 | 5.58 | 5.66 |
| 实验室服务(%) | 74.99 | 80.58 | 75.36 | 80.10 |
| 化学和制剂工艺开发及生产(%) | - | - | - | 17.78 |
| CMC(%) | 24.36 | 19.41 | 23.92 | - |